CLOs on the Move

QUATRx Pharmaceuticals Company

www.quatrx.com

 
QUATRx Pharmaceuticals Company is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.quatrx.com
  • 777 E Eisenhower Pkwy
    Ann Arbor, MI USA 48108
  • Phone: 734.913.9900

Executives

Name Title Contact Details

Similar Companies

Allergene

Allergene is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Patara Pharma

Patara Pharma is a biopharmaceutical company developing a new therapy for the treatment of allergic and immunologic diseases and conditions that affect orphan patient populations. We completed a Phase 1 clinical trial with favorable results and have initiated Phase 2 clinical trials for several undisclosed indications that will read-out by the end of 2015.

IVFCRYO

Ensuring safe and secure management of reproductive specimens world wide. Tank failures happen. Specimens don’t have to be lost because of that. We can help.

Obatala Sciences

Obatala Sciences offers contract research services and research products to laboratories in industry and in academia. Our clients include US government entities, contract research organizations, non-profit organizations, and academic research laboratories. Our areas of expertise include obesity, diabetes, energy metabolism, musculoskeletal system biology, and wound healing. ObaCell, a unique fat tissue model, is a great tool for disease modeling and drug screening. Obatala Sciences can provide data in various areas depending on your interest including proteomics, genomics, functionality, and adipokine secretion. We also have the capability of forming white or brown fat tissue upon request.

Anokion

Anokion, a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), is focused on applying the company`s antigen-specific immune tolerance technology to reduce the immunogenicity of therapeutic proteins and to treat autoimmune and allergic diseases. As a platform technology, Anokion`s approach to antigen-specific tolerance can be translated to virtually any protein in numerous clinical indications.